Cibc Private Wealth Group Reduces $637K in Bristol-Myers Squibb Company ($BMY)
CIBC Private Wealth Group cut its Bristol-Myers Squibb holdings by 3.9%, now holding 268,354 shares.
Key Points
- CIBC Private Wealth Group trimmed its stake in Bristol-Myers Squibb by 10,873 shares, a 3.9% decrease, as of its latest SEC filing.
- Bristol-Myers Squibb shares traded near $58.56 on Tuesday, with a market cap of $117.5 billion and a P/E ratio of 16.1.
- Insider activity included buying and selling by executives, while analysts maintained varied ratings with price targets ranging from $54 to $75.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
CIBC Private Wealth Group has reduced its holdings in Bristol-Myers Squibb Company (NYSE: BMY) by 10,873 shares, according to its latest filing with the SEC. This represents a 3.9% decrease in its position, leaving the group with 268,354 shares valued at approximately $15.7 million as of the reporting period.
What Changed in CIBC Private Wealth Group's Bristol-Myers Squibb Position
CIBC Private Wealth Group trimmed its stake in Bristol-Myers Squibb by 10,873 shares, resulting in a 3.9% decrease in its position. The firm now holds 268,354 shares, valued at around $15.7 million.
Other Institutional Activity in Bristol-Myers Squibb
BlackRock, Inc. reduced its holdings by 5,142,518 shares, now holding 171,682,888 shares worth about $10.4 billion. Vanguard Capital Management LLC opened a new position with 132,320,240 shares, valued at approximately $8 billion. State Street Corp increased its holdings by 584,476 shares to 98,564,914 shares, valued at roughly $6 billion. JPMorgan Chase & Co grew its position by 17,107,541 shares, a 22.7% increase, to hold 92,475,194 shares worth $5.5 billion. Meanwhile, Charles Schwab Investment Management Inc reduced its stake by 10,207,019 shares, a 14.3% decrease, leaving it with 61,115,373 shares valued at $3.7 billion.
Bristol-Myers Squibb Company Stock Down 12.0%
Shares of NYSE:BMY traded near $58.56 on Tuesday. Bristol-Myers Squibb has a market cap of $117.5 billion, a P/E ratio of 16.1, and a forward P/E of 9.3. The stock's beta is 0.238, indicating lower volatility compared to the market. It has a 52-week low of $42.52 and a high of $62.89, with a 50-day moving average of $57.09 and a 200-day moving average of $53.80. The company's current ratio is 1.42, quick ratio is 1.178, and its debt-to-equity ratio stands at 230.967.
$BMY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Bristol-Myers Squibb reported revenue of $48.48 billion, with a revenue growth of 2.6%. Its net margin was 15%, and the return on equity was 38.7%. The company is set to announce its next earnings on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS beat estimates by 10.4%. Revenue beat estimates by 4.3%.
-
Profit surprise
EBITDA missed by 13 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
- Analyst signal
-
Earnings quality
Gross margin up 4.7 points. Operating margin down 3.0 points. Positive free cash flow.
Earnings Call Summary
Bristol delivered a solid first quarter with revenue of 11.5 billion dollars, up 1 percent year over year, and earnings per share of 1.58 dollars, beating Wall Street by 10 percent. The growth portfolio grew 9 percent, led by strong performances from Eliquis at 4.1 billion dollars and Breyanzi up 53 percent. Management highlighted progress across pipeline programs including positive data for Pumitamig and upcoming late-year readouts for Factor XI inhibitor Milvexian and Cobenfy in Alzheimer's disease psychosis.
Guidance Bristol reaffirmed its 2026 financial targets and said the company is tracking toward the upper end of guidance. The management team noted strong momentum in the growth portfolio and multiple clinical readouts expected in the second half of the year, including Milvexian in atrial fibrillation and Cobenfy in Alzheimer's psychosis.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Dividend
Bristol-Myers Squibb pays an annual dividend rate of $2.52 per share, yielding 4.38%. The dividend payout ratio is 70.03%.
Insider Buying and Selling at Bristol-Myers Squibb Company
Insider transactions include Julia Haller buying 20,460 shares at $53.76 on June 15, 2026, and selling an equal amount on the same day. Wendy Short, EVP of Corporate Affairs, sold 3,876 shares at $54.72 on June 3, 2026, while also buying 8,040 shares without a disclosed price. Adam Lenkowsky, EVP and Chief Commercial Officer, sold 203 shares on May 1, 2026.
Analysts Set New Price Targets
On April 9, 2026, B of A Securities maintained a 'buy' rating with a $67 price target. Cantor Fitzgerald maintained a 'hold' rating with a $54 target on April 8, 2026. HSBC maintained a 'hold' rating with a $60 target on March 17, 2026. The consensus among 25 analysts is a target mean price of $63.08.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey. It focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company operates in several therapeutic areas including oncology, hematology, immunology, cardiovascular, and neuroscience. Dr. Christopher S. Boerner Ph.D. serves as the CEO, and the company employs approximately 32,500 people worldwide.
Bottom Line
The recent 13F filing by CIBC Private Wealth Group shows a reduction in its stake in Bristol-Myers Squibb, highlighting the dynamic nature of institutional investments. Investors closely watch these filings for insights into institutional sentiment. While these filings are backward-looking, they provide a snapshot of how major funds are positioning themselves in the market.
Get Bristol-Myers Squibb Company alerts
New 13F filings, insider trades, and analyst moves on $BMY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.